Hermetica Superfood Encyclopedia
The Short Answer
Parthenolide is a sesquiterpene lactone derived primarily from feverfew (Tanacetum parthenium) that exerts anticancer effects by covalently binding to and inhibiting the IKKβ kinase, thereby blocking NF-κB transcription factor activation. Preclinical research has demonstrated selective cytotoxicity toward leukemic stem cells and solid tumor cells while largely sparing normal hematopoietic cells.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordparthenolide benefits
Synergy Pairings5
Parthenolide — botanical close-up
Health Benefits
Origin & History
Natural habitat
Parthenolide is a sesquiterpene lactone primarily extracted from Tanacetum parthenium (feverfew), a traditional medicinal plant in the Asteraceae family. It has also been identified in other plant species used in traditional Chinese medicine. Extraction typically involves solvent-based methods from dried plant material, with standardized preparations quantifying parthenolide content by mass spectrometry or high-performance liquid chromatography (HPLC).
“Feverfew has been used in European herbalism for centuries, documented since medieval times for migraine prophylaxis, fever reduction, and anti-inflammatory purposes. Traditional preparations included dried leaf infusions and tinctures. Parthenolide itself was not isolated in traditional use but represents the modern understanding of feverfew's active principle.”Traditional Medicine
Scientific Research
The only published human trial is a Phase I dose escalation study (PubMed: 15122077) that found feverfew extract containing 1-4 mg daily parthenolide was well-tolerated but achieved no detectable plasma concentrations, severely limiting bioavailability. Extensive preclinical studies demonstrate anticancer effects in colorectal cancer, leukemia, melanoma, and glioblastoma models (PMC8962426, PubMed: 28522946, 19949351, 18277052). No Phase II or III trials have been completed.
Preparation & Dosage
Traditional preparation
Clinical trial used standardized feverfew extract containing 1-4 mg parthenolide daily, though no therapeutic plasma levels were achieved. Preclinical studies use purified parthenolide at 1-10 μmol/L in vitro or the soluble analogue DMAPT in animal models. Future clinical use would require purified formulations or chemical modifications to overcome poor oral bioavailability. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Parthenolide is a sesquiterpene lactone compound (molecular formula C15H20O3, MW 248.32 g/mol) found primarily in feverfew (Tanacetum parthenium) at concentrations of 0.2–0.9% dry weight in leaves. It is not a conventional nutrient and contains no meaningful macronutrients, vitamins, or minerals in isolation. The bioactive core is its α-methylene-γ-lactone ring and an epoxide group, which are responsible for its reactivity with biological targets including NF-κB (IKKβ subunit alkylation) and STAT3. Oral bioavailability is limited due to poor aqueous solubility (~0.013 mg/mL) and rapid metabolism; a synthetic water-soluble analog, dimethylaminoparthenolide (DMAPT), was developed specifically to overcome this limitation. Typical experimental doses in preclinical models range from 1–10 μM in vitro; no established human therapeutic dose exists. Feverfew standardized extracts delivering ~0.2–0.6 mg parthenolide per dose are commercially available, though systemic exposure remains poorly characterized in humans.
How It Works
Mechanism of Action
Parthenolide alkylates a cysteine residue (Cys179) on IκB kinase beta (IKKβ), preventing phosphorylation and degradation of IκBα, which sequesters NF-κB in the cytoplasm and suppresses pro-survival gene transcription. Concurrently, parthenolide depletes intracellular glutathione and generates reactive oxygen species, selectively overwhelming the antioxidant capacity of cancer cells. It also inhibits mTORC1 signaling by activating AMPK and suppressing Akt phosphorylation, further reducing proliferative signaling in malignant cells.
Clinical Evidence
The vast majority of parthenolide evidence comes from in vitro cell culture studies and murine xenograft models; no completed randomized controlled human trials have evaluated parthenolide as a standalone anticancer agent. Preclinical studies show it eliminates CD34+/CD38- acute myeloid leukemia (AML) stem cells at concentrations of 5–10 µM while sparing normal CD34+ progenitors. In xenograft models, parthenolide enhanced docetaxel-induced apoptosis in prostate cancer cells and sensitized colorectal cancer cells to TRAIL-mediated death by upregulating DR4/DR5 death receptors. A water-soluble prodrug analog, DMAPT (dimethylaminoparthenolide), was developed to address poor oral bioavailability and has shown activity in canine lymphoma trials, but human Phase I/II data remain unpublished or pending.
Safety & Interactions
Parthenolide and feverfew-derived supplements are generally associated with mild adverse effects including oral ulcers (post-discontinuation rebound), gastrointestinal upset, and allergic contact dermatitis, particularly in individuals sensitive to other Asteraceae family plants. Because parthenolide inhibits platelet aggregation by blocking thromboxane synthesis, concurrent use with anticoagulants (warfarin, heparin) or antiplatelet drugs (aspirin, clopidogrel) may increase bleeding risk. It may potentiate or alter the pharmacokinetics of CYP3A4-metabolized chemotherapeutics, warranting caution in oncology settings without medical supervision. Parthenolide is contraindicated during pregnancy due to its uterine-stimulating properties and should be avoided while breastfeeding due to insufficient safety data.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
(1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-oneFeverfew lactoneTanacetum parthenium extractChrysanthemum parthenium lactonePTLSesquiterpene lactone from feverfew
Frequently Asked Questions
Can parthenolide kill cancer stem cells?
In vitro studies show parthenolide selectively eliminates AML stem cells (CD34+/CD38- phenotype) at concentrations of 5–10 µM by inducing oxidative stress and blocking NF-κB survival signaling, while sparing normal hematopoietic progenitor cells. This selectivity has also been demonstrated in breast and prostate cancer stem cell models. However, these findings are preclinical and have not yet been confirmed in human clinical trials.
What is the difference between parthenolide and DMAPT?
DMAPT (dimethylaminoparthenolide) is a water-soluble prodrug analog of parthenolide engineered to overcome parthenolide's poor oral bioavailability, which is limited by its lipophilicity and rapid metabolism. DMAPT converts back to parthenolide in vivo and achieves substantially higher plasma concentrations following oral dosing in animal models. It has demonstrated efficacy in canine spontaneous lymphoma trials, but human clinical data are not yet publicly available.
Does parthenolide interact with chemotherapy drugs?
Preclinical studies demonstrate that parthenolide sensitizes cancer cells to TRAIL-induced apoptosis by upregulating death receptors DR4 and DR5, and enhances docetaxel cytotoxicity in prostate cancer xenograft models by suppressing NF-κB-driven survival genes like Bcl-2 and survivin. It may also inhibit CYP3A4 enzyme activity, potentially altering plasma levels of chemotherapeutic agents metabolized through this pathway. Anyone undergoing chemotherapy should consult an oncologist before using parthenolide-containing supplements due to these interaction risks.
How much parthenolide is in feverfew supplements?
Standardized feverfew (Tanacetum parthenium) supplements typically contain 0.2–0.7% parthenolide by dry weight, with migraine-focused doses usually providing 100–300 mg of feverfew extract delivering approximately 0.2–0.6 mg of parthenolide per dose. This is significantly lower than the 5–10 µM concentrations used in anticancer cell studies, meaning standard supplement doses are unlikely to achieve therapeutically relevant tissue concentrations for oncology purposes. Quality varies widely between products, so third-party tested formulations are recommended.
Is parthenolide safe to take long-term?
Long-term safety data for isolated parthenolide supplements are limited, but feverfew has been used for decades with a generally mild safety profile at conventional doses. The most documented risk of prolonged use is 'post-feverfew syndrome' upon abrupt discontinuation, characterized by rebound headaches, anxiety, and muscle stiffness. Due to its antiplatelet activity via thromboxane B2 inhibition and potential hormonal effects, long-term use is not recommended without medical oversight, and it should be avoided in people with bleeding disorders or those taking blood-thinning medications.
What is the current clinical trial status for parthenolide as a cancer treatment?
As of now, parthenolide has no completed human clinical trials for cancer treatment, though extensive preclinical research demonstrates its ability to suppress NF-κB and mTOR pathways in cancer cells. Several early-stage trials are investigating parthenolide derivatives and synthetic analogs like DMAPT in hematologic malignancies, but results remain preliminary. The gap between promising laboratory findings and human efficacy data means parthenolide cannot yet be considered an established cancer therapy outside of research settings.
Which cancer cell types have shown the most sensitivity to parthenolide in research?
Parthenolide has demonstrated particular efficacy against leukemic cells, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) cells, primarily through its ability to selectively target cancer stem cells while sparing normal hematopoietic cells. Preclinical studies also show activity against breast cancer, lung cancer, and multiple myeloma cells, though sensitivity varies by cell line and molecular subtype. The selective toxicity to malignant cells versus healthy cells like human microvascular endothelial cells (HMECs) makes parthenolide particularly interesting for therapeutic development.
Does parthenolide bioavailability differ significantly between feverfew leaf extracts and isolated parthenolide supplements?
Feverfew leaf extracts contain variable parthenolide concentrations (typically 0.4–1.5% by weight) depending on plant source and extraction method, which limits standardization and bioavailability prediction in supplement form. Isolated or semi-synthetic parthenolide compounds may offer more consistent dosing and potentially improved absorption, though human pharmacokinetic studies comparing these forms remain limited. The presence of other feverfew phytochemicals in whole extracts may influence parthenolide absorption through enteric interactions, but this has not been systematically characterized in humans.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w parthenolide curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
